Northwest Biotherapeutics (NWBO) Cash from Financing Activities (2010 - 2026)

Northwest Biotherapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $9.2 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 21.51% year-over-year to $9.2 million in Q1 2026; TTM through Mar 2026 was $46.8 million, a 17.06% decrease from a year earlier, with the FY2025 full-year figure at $49.3 million, down 13.13% from the prior year.
• Cash from Financing Activities slipped to $9.2 million in Q1 2026 per NWBO's latest filing, from $13.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $17.1 million in Q2 2024 and bottomed at $3.9 million in Q1 2022.
• The 5-year median for Cash from Financing Activities is $12.1 million (2024), against an average of $12.4 million.
• Across the five-year window, Cash from Financing Activities tumbled 63.57% in 2022 and surged 220.97% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at $11.4 million in 2022, then increased by 26.99% to $14.4 million in 2023, then grew by 10.59% to $15.9 million in 2024, then slipped by 14.77% to $13.6 million in 2025, then plunged by 32.23% to $9.2 million in 2026.
• Per Business Quant, the three latest NWBO Cash from Financing Activities figures stand at $9.2 million (Q1 2026), $13.6 million (Q4 2025), and $11.6 million (Q3 2025).